CAMBRIDGE, Mass. — March 3, 2026 — Leads & Copy — Intellia Therapeutics, Inc. (Nasdaq: NTLA) presented details on four posters at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) this past weekend in Philadelphia, Pennsylvania.
The posters, which are available on intelliatx.com on the Scientific Publications & Presentations page, covered topics ranging from the long-term durability and safety of Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002) to the challenges of chronic medications for hereditary angioedema (HAE) patients.
One poster presentation, titled “Long-Term Durability and Safety of Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002) 50 mg in Patients with Hereditary Angioedema,” featured a pooled Phase 1/2 analysis (n=32) that showed a single 50 mg dose of lonvo-z led to significant reductions in plasma kallikrein across all patients with up to three years of follow-up. The mean monthly attack rate was consistently ≤0.2, representing a mean reduction of 96% in HAE attacks from baseline through last follow-up. Of the 32 patients, 31 (97%) were attack-free and LTP-free as of the data cutoff, with the attack-free and LTP-free periods ranging from 2 months to 3 years with follow-up ongoing.
Markus Magerl, M.D, Professor, Head of Clinical Trials, Charité – Universitätsmedizin Berlin Institute of Allergology, presented the poster.
Another poster, “Evolving Treatment Goals to Achieve Freedom from Attacks and Long-Term Prophylaxis Following a One-Time Treatment with Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002),” highlighted that achieving an attack-free status and minimizing treatment burden are primary treatment goals for HAE experts and patients. Of the 28 patients with >6 months of follow-up after receiving a one-time 50 mg treatment of lonvo-z in a pooled Phase 1/2 analysis, 86% were attack-free and LTP-free for >6 months.
Aleena Banerji, M.D., Professor at Harvard Medical School, Clinical Director of the Allergy and Clinical Immunology Unit at Massachusetts General Hospital, presented the findings.
A third poster, “Quantitative Systems Biology Modeling Estimates Extent of Excessive Kallikrein Generation in Hereditary Angioedema Patients,” suggested that HAE with significant C1-esterase inhibitor deficiency generates excess plasma kallikrein compared to healthy individuals, directly correlating with bradykinin increases. The model also showed that an 85% reduction in prekallikrein reduced peak free kallikrein and peak bradykin to near normal ranges, consistent with clinical observations from a 50 mg dose of lonvo-z.
Allen Kaplan, M.D., Professor, Department of Medicine, Medical University of South Carolina, presented the poster.
The final poster, “Chronic Medications Pose Challenges for People Living with Hereditary Angioedema,” revealed that among 100 surveyed U.S. patients with HAE, 34% reported having at least one attack per month, and only 20% reported being attack-free in the prior year. Most respondents indicated that eliminating lifetime chronic medication use and enhancing efficacy are the most important ways to improve their current therapy.
Paula Busse, M.D., Professor, Department of Medicine, Division of Clinical Immunology, Mount Sinai Hospital, presented the poster.
Lonvo-z, based on CRISPR/Cas9 technology, is being investigated in the HAELO Phase 3 clinical trial in HAE and has the potential to become the first one-time treatment for HAE by inactivating the kallikrein B1 (KLKB1) gene. It has received several regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.
Source: Intellia Therapeutics
